Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Siltuximab (Primary)
- Indications Giant lymph node hyperplasia; Multiple myeloma; Paraproteinaemia
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 08 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2016 Status changed from not yet recruiting to recruiting.